11 recruiting, 9 completed, 2 unknown, 1 active not recruiting. 11 Phase 1, 6 Phase 2, 4 Phase 3, 3 Not applicable, 2 Early Phase 1.
Follow Sinotau Pharmaceutical Group: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy Fasting XTR003/¹⁸F-FDG PET myocardial metabolic imaging, Glucose-loaded ¹⁸F-FDG PET Myocardial Metabolic Imaging - Ischemic Cardiomyopathy, Heart Failure | Phase 2 | Recruiting | Sinotau Pharmaceutical Group | 40 | 2025-12-18 | 2026-03-02 |
| Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR) XTR004 - Coronary Artery Disease(CAD) | Phase 3 | Recruiting | Sinotau Pharmaceutical Group | 395 | 2025-11-14 | 2026-03-03 |
| Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma 68Ga-XT771 - Clear Cell Renal Cell Carcinoma and Glioblastoma | Early Phase 1 | Recruiting | Chinese PLA General Hospital | 15 | 2025-06-27 | 2025-07-16 |
| A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults Flotufolastat F-18 Injection - Prostate Cancer | Phase 1 | Recruiting | Sinotau Pharmaceutical Group | 6 | 2025-06-07 | 2025-09-02 |
| Diagnostic Efficacy and Safety of Flotufolastat F-18 Injection in Subjects With Biochemical Recurrence of Prostate Cancer Flotufolastat F-18 Injection - Prostate Cancer | Not applicable | Recruiting | Sinotau Pharmaceutical Group | 121 | 2025-03-14 | 2025-08-11 |
| Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis XTR004 - Myocardial Perfusion Imaging, Diagnostic Certainty | Phase 2 | Terminated | Sinotau Pharmaceutical Group | 17 | 2024-12-19 | 2026-01-12 |
| Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD XTR006 - Alzheimer Disease, Neurofibrillary Tangle | Phase 3 | Recruiting | Sinotau Pharmaceutical Group | 354 | 2024-11-20 | 2025-08-11 |
| A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens [225Ac]Ac-DOTATATE - Neuroendocrine Neoplasm | Phase 1 | Recruiting | Peking University Cancer Hospital & Institute | 36 | 2024-09-29 | 2025-06-26 |
| A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate Cancer [177Lu]Lu-PSMA-XT - mCRPC | Phase 1 | Recruiting | Jinming Zhang | 36 | 2024-08-20 | 2025-07-31 |
| A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms Lutetium[177Lu] Oxodotreotide Injection - Advanced Neuroendocrine Neoplasm | Phase 2 / Phase 3 | Recruiting | Sinotau Pharmaceutical Group | 85 | 2024-06-11 | 2026-07-17 |
| A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors [177Lu]Lu-XT117 - Advanced Solid Tumor | Phase 1 | Recruiting | Ruimin Wang | 20 | 2024-01-01 | 2024-01-18 |
| A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors [177Lu]Lu-XT117 - Advanced Solid Tumor | Phase 1 | Recruiting | Xinlu Wang | 20 | 2024-01-01 | 2024-01-09 |
| Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer Phase I:[177Lu]Lu-XT033 Injection, Phase II:[177Lu]Lu-XT033 Injection - Prostate Cancer | Phase 1 / Phase 2 | Unknown | Sinotau Pharmaceutical Group | 32 | 2023-09-13 | 2024-05-03 |
| Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors 2.5-3.5mCi 64Cu-FAPI-XT117, 3.5-4.5mCi 64Cu-FAPI-XT117, 4.5-5.5mCi 64Cu-FAPI-XT117 - Malignant Solid Tumors | Phase 1 | Completed | The First Affiliated Hospital of Guangzhou Medical University | 15 | 2023-07-26 | 2023-12-26 |
| A Study to Evaluate XTR006 in Chinese Volunteers XTR006 - Alzheimer Disease | Phase 1 | Completed | Sinotau Pharmaceutical Group | 10 | 2023-06-12 | 2024-05-03 |
| First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors 2-4 mCi 68Ga/64Cu-FAPI-XT117, 4-6 mCi 68Ga/64Cu-FAPI-XT117, 6-8 mCi 68Ga/64Cu-FAPI-XT117 - Malignant Solid Tumors | Phase 1 | Completed | Chinese PLA General Hospital | 14 | 2022-12-07 | 2023-12-20 |
| Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects XTR006 - Alzheimer Disease | Not applicable | Completed | Sinotau Pharmaceutical Group | 42 | 2022-09-01 | 2024-05-03 |
| A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs Lutetium[177Lu] Oxodotreotide Injection, Octreotide LAR - Neuroendocrine Tumors | Phase 3 | Active not recruiting | Sinotau Pharmaceutical Group | 196 | 2022-08-31 | 2025-09-05 |
| Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD XTR004 - Coronary Artery Disease (CAD) | Phase 2 | Completed | Sinotau Pharmaceutical Group | 83 | 2022-02-15 | 2023-06-02 |
| XTR003 PET Radiotracer for the Detection of Viable Myocardium XTR003 - Ischemic Heart Disease (IHD) | Phase 2 | Completed | Sinotau Pharmaceutical Group | 51 | 2021-12-15 | 2023-06-02 |
Showing 20 of 24. Sign in to see all of them.
Coronary Artery Disease (5) · Alzheimer Disease (4) · Prostatic Neoplasms (3) · Myocardial Ischemia (2) · Neuroendocrine Tumors (2) · Brain Diseases (1) · Carcinoma, Renal Cell (1) · Central Nervous System Diseases (1) · Dementia (1) · Glioblastoma (1) · Heart Failure (1) · Mental Disorders (1) · Nervous System Diseases (1) · Neurocognitive Disorders (1) · Neurodegenerative Diseases (1)
lutetium Lu 177 dotatate (2) · 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (1) · Octreotide (1)
China (23)
Ruimin Wang (2) · Dingwei Ye (1) · Jianming Xu (1) · Jinming Zhang (1) · Jiong Shi, Doctor (1) · Zhi Yang (1)